Understand the source comparison
KPV for Skin Conditions: Administration Route Comparison
Subcutaneous injection 500–1000mcg daily 10–14 days for acute inflammation; 6–12 weeks for chronic remodelling Systemic circulation. Whole-body anti-inflammatory effect Moderate. Requires reconstitution, sterile technique, injection site rotation Widespread in
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Subcutaneous injection
- 500–1000mcg daily
- 10–14 days for acute inflammation; 6–12 weeks for chronic remodelling
- Systemic circulation. Whole-body anti-inflammatory effect
- Moderate. Requires reconstitution, sterile technique, injection site rotation
- Widespread inflammatory dermatoses (generalised eczema, extensive psoriasis, systemic conditions with skin manifestations)
- Topical application
- 1–2mg per application site, twice daily
- 7–10 days for localised lesion improvement
- Localised dermal penetration. Concentrated at application site
- High. Requires penetration enhancer formulation (DMSO or propylene glycol base)
- Localised plaques, facial rosacea, isolated atopic dermatitis patches
- Oral (experimental)
- 2–5mg daily
- Variable. Depends on GI absorption and first-pass metabolism
- Systemic after hepatic metabolism. Lower bioavailability than injection
- Low. Can be mixed into liquid
- Inflammatory bowel disease with dermatological manifestations; not standard for primary skin conditions
- Professional Assessment
- Subcutaneous injection offers the most consistent plasma levels and predictable anti-inflammatory response for widespread conditions. Topical application delivers higher local concentrations without systemic exposure. Preferred for facial or cosmetically sensitive areas. Oral administration has the lowest bioavailability (~15–25%) but may be appropriate when injection compliance is a barrier.